目的 探討血塞通聯(lián)合尼莫地平對(duì)急性腦梗死患者認(rèn)知功能的影響。方法 選取2013年3月—2018年3月在漢中市人民醫(yī)院就診的急性腦梗死患者105例，隨機(jī)分為觀察組（n=53）和對(duì)照組（n=52）。對(duì)照組在基礎(chǔ)治療基礎(chǔ)上給予患者口服尼莫地平片30 mg，3次/d。觀察組在對(duì)照組基礎(chǔ)上將注射用血塞通400 mg加入500 mL 0.9%氯化鈉注射液中靜脈滴注，1次/d。均治療14 d。對(duì)比兩組簡(jiǎn)易精神狀態(tài)檢查量表（MMSE）評(píng)分、蒙特利爾認(rèn)知功能評(píng)估量表（MoCA）評(píng)分、美國(guó)國(guó)立衛(wèi)生研究院卒中量表（NIHSS）評(píng)分和Barthel指數(shù)（BI）評(píng)分及不良反應(yīng)發(fā)生情況。結(jié)果 與對(duì)照組總有效率61.54%比較，觀察組總有效率88.68%顯著升高，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后兩組MoCA評(píng)分和MMSE評(píng)分與治療前比較均不同程度升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組MoCA評(píng)分和MMSE評(píng)分升高更為明顯，組間差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后兩組NIHSS評(píng)分明顯降低，BI評(píng)分明顯升高，同組治療前后比較差異均具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組NIHSS評(píng)分降低更為顯著，BI評(píng)分升高更為顯著，組間差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組不良反應(yīng)發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 血塞通聯(lián)合尼莫地平可有效改善急性腦梗死患者的認(rèn)知功能，值得臨床推廣。

Objective To investigate the effect of Xuesaitong combined with nimodipine on cognitive function in patients with acute cerebral infarction. Methods 105 patients with acute cerebral infarction in our hospital from March 2013 to March 2018 were randomly divided into the observation group (Xuesaitong + nimodipine, n=53) and the control group (nimodipine, n=52). The MMSE score, MoCA score, NIHSS score, Barthel index score and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was significantly higher than that of the control group (P<0.05). After treatment, the MoCA scores and MMSE scores in the two groups were significantly higher than those before treatment (P<0.05), and the increase in the MoCA score and the MMSE score in the observation group was more obvious (P<0.05). After treatment, the difference of NIHSS score and BI score between the two groups was statistically significant (P<0.05), and the decrease of NIHSS score in the observation group was more significant (P<0.05), and the increase of BI score was more significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Xuesaitong combined with nimodipine can effectively improve the cognitive function of patients with acute cerebral infarction, and is worthy of clinical promotion.